BioSpace News Archive

RepliCel Life Sciences Inc. is pleased to announce the completion, last week, of an inspection of RepliCel’s NBDS cell therapy manufacturing at its Austrian contract manufacturing facility owned and operated by Innovacell KK.

Immunic, Inc. announced that the company will release its financial results for the second quarter ended June 30, 2022, including a corporate update, on Thursday, August 4, 2022, before the opening of the U.S. financial markets.

BD, a leading global medical technology company, announced it has acquired MedKeeper, a provider of modern, cloud-based pharmacy management applications.

Smart Immune SAS announced the members of its newly-formed Scientific Advisory Board, all world-leading experts in fields including thymus rejuvenation, thymic biology, immune reconstitution and immune-oncology.

Applied Therapeutics, Inc. (Nasdaq: APLT), a clinical-stage biopharmaceutical company developing a pipeline of novel drug candidates against validated molecular targets in indications of high unmet medical need, today announced its sponsorship and presentations at the 2022 Galactosemia Foundation Conference being held July 28-30 in Orlando, Florida.

Voyager Therapeutics, Inc., a gene therapy company developing life-changing treatments and next-generation adeno-associated virus capsids, announced the appointment of Catherine J. Mackey, Ph.D. to its Board of Directors.

Tonix Pharmaceuticals Holding Corp. (Nasdaq: TNXP) (Tonix or the Company), a clinical-stage biopharmaceutical company, today announced a collaboration with the Kenya Medical Research Institute (KEMRI) to plan, seek regulatory approval for and conduct a Phase 1 clinical study in Kenya to develop TNX-8011 as a vaccine to protect against monkeypox and smallpox

Seattle-based Precision Oncology company SEngine Precision Medicine has now raised a total of $19M, following the recent closing of a $10M Series A2, as it continues to commercialize a platform that matches cancer patients to the right drug and also drives drug discovery.

Algernon Pharmaceuticals Inc. (the “Company” or “Algernon”) (CSE: AGN) (FRANKFURT: AGW0) (OTCQB: AGNPF) a clinical stage Canadian pharmaceutical development company, is pleased to announce additional results from its Phase 2a Study of NP-120 (“Ifenprodil”) for idiopathic pulmonary fibrosis (“IPF”) and chronic cough.

Bio-Techne Corporation (NASDAQ: TECH) today announced the signing of an exclusive licensing agreement to commercialize The University of Dundee’s BromoTAG® system and fund the recruitment of postdoctoral researchers at the University’s Centre for Targeted Protein Degradation (CeTPD).